INT

Thanks for that. It's not the NADINA 5 yr data, which hasn't matured. It's 5yr pooled data from various trials and case studies. I didn't check if the phase 2 Prado trial was in the mix but it probably is. My estimate of 70% RFS at 5 yr wasn't off by much. OS is a hugely important endpoint but I think we're getting good at keeping people alive even though they're seeing cancer come back. Costs & prep timing aside (huge handwave), the INT effects were genuinely impressive added to pembro. I don

I get your argument. If Moderna started the phase 2 and 3 trials now would they use neoadjuvant regimen as comparator? I don't know, someone should ask that. You're assuming that INT won't improve the neoadjuvant regimen similarly? Don't know. We also don't know if INT can be used as a monotherapy or even should be? I don't know the preclinical data there. What about time frame? What happens after 2 years with these therapies including neo ICI & INT combo? It appears that neo ICI has good long